[go: up one dir, main page]

AU2001294820A1 - Methods for in vivo reduction of free radical levels and compositions useful therefor - Google Patents

Methods for in vivo reduction of free radical levels and compositions useful therefor

Info

Publication number
AU2001294820A1
AU2001294820A1 AU2001294820A AU9482001A AU2001294820A1 AU 2001294820 A1 AU2001294820 A1 AU 2001294820A1 AU 2001294820 A AU2001294820 A AU 2001294820A AU 9482001 A AU9482001 A AU 9482001A AU 2001294820 A1 AU2001294820 A1 AU 2001294820A1
Authority
AU
Australia
Prior art keywords
methods
free radical
compositions useful
useful therefor
vivo reduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294820A
Inventor
Ching-San Lai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical College of Wisconsin Research Foundation Inc
Original Assignee
Medical College of Wisconsin Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical College of Wisconsin Research Foundation Inc filed Critical Medical College of Wisconsin Research Foundation Inc
Publication of AU2001294820A1 publication Critical patent/AU2001294820A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/14—Dithiocarbamic acids; Derivatives thereof
    • C07C333/16—Salts of dithiocarbamic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001294820A 2000-09-27 2001-09-26 Methods for in vivo reduction of free radical levels and compositions useful therefor Abandoned AU2001294820A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/672,140 US6469057B1 (en) 1995-06-02 2000-09-27 Methods for in vivo reduction of free radical levels and compositions useful therefor
US09672140 2000-09-27
PCT/US2001/030306 WO2002026225A1 (en) 2000-09-27 2001-09-26 Methods for in vivo reduction of free radical levels and compositions useful therefor

Publications (1)

Publication Number Publication Date
AU2001294820A1 true AU2001294820A1 (en) 2002-04-08

Family

ID=24697316

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294820A Abandoned AU2001294820A1 (en) 2000-09-27 2001-09-26 Methods for in vivo reduction of free radical levels and compositions useful therefor

Country Status (3)

Country Link
US (3) US6469057B1 (en)
AU (1) AU2001294820A1 (en)
WO (1) WO2002026225A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816403B2 (en) * 1998-09-08 2010-10-19 University Of Utah Research Foundation Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same
US6548540B2 (en) * 1998-09-08 2003-04-15 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
MXPA04011416A (en) * 2002-05-17 2005-09-30 Othera Pharmaceuticals Inc Amelioration of the development of cataracts and other opthalmic diseases.
WO2004093860A1 (en) * 2003-04-21 2004-11-04 Pfizer Inc. Inhibitors of sars related coronavirus proteinase
US20040235952A1 (en) * 2003-05-05 2004-11-25 Agouron Pharmaceuticals, Inc. Inhibitors of severe acute respiratory syndrome (SARS) 3C-like proteinase
US7825134B2 (en) * 2003-05-19 2010-11-02 Othera Holding, Inc. Amelioration of cataracts, macular degeneration and other ophthalmic diseases
US20050025804A1 (en) * 2003-07-28 2005-02-03 Adam Heller Reduction of adverse inflammation
EP2052720A3 (en) * 2003-11-20 2009-05-06 Othera Holding, Inc. Use of at least one hydroxylamine compound for the treatment of eye disease
US20070065486A1 (en) * 2004-05-21 2007-03-22 Migco Limited Migraine remedy
WO2006127592A2 (en) * 2005-05-26 2006-11-30 Othera Pharmaceuticals, Inc. Use of hydroxylamine derivates for inhibiting vitrectomy-induced cataracts
GB0518890D0 (en) * 2005-09-15 2005-10-26 Ucl Biomedica Plc Method of determining damage to skin
WO2012104204A1 (en) 2011-01-31 2012-08-09 Vifor (International) Ag Iron-carbohydrate complex compounds for the intravenous therapy of malaria
WO2016054079A1 (en) 2014-09-29 2016-04-07 Zyomed Corp. Systems and methods for blood glucose and other analyte detection and measurement using collision computing
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing
AU2021280407A1 (en) * 2020-05-27 2023-02-02 Croft Infrastructure Designs Pty Ltd Methods of antipathogenic treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380747A (en) * 1992-10-30 1995-01-10 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5741815A (en) * 1995-06-02 1998-04-21 Lai; Ching-San Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US5756540A (en) * 1995-06-02 1998-05-26 Mcw Research Foundation, Inc. Methods for in vivo reduction of nitric oxide levels and compositions useful therefor

Also Published As

Publication number Publication date
WO2002026225A1 (en) 2002-04-04
US6469057B1 (en) 2002-10-22
US20030203887A1 (en) 2003-10-30
US20030040511A1 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
AU2001241474A1 (en) Biosensor compositions and methods of use
EP1157707B8 (en) Method and composition for deforming soft tissues
AU2778801A (en) Antisense compositions and methods
AU2001239947A1 (en) Methods and compositions for regulating adipocytes
AU2001266864A1 (en) Sulfur containing dermatological compositions and methods for reducing malodors in dermatological compositions
AUPQ419099A0 (en) Novel compositions and methods
AU2002357119A1 (en) Mitocidal compositions and methods
AU4243397A (en) Methods for in vivo reduction of iron levels and compositions useful therefor
AU2001234437A1 (en) Deicing compositions and methods of use
AU3887900A (en) Protamine fragment compositions and methods of use
AU4340700A (en) Methods and compositions for use in the treatment of hyperlipidemia
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
AU2001294820A1 (en) Methods for in vivo reduction of free radical levels and compositions useful therefor
AU2001271031A1 (en) Cosmetic compositions for reducing and method of using the same
IL154756A0 (en) Methods and compositions for promoting the maturation of monocytes
AU2002331890A1 (en) Compositions and methods involved in bone growth
WO2001091700A8 (en) Composition and method for enhancing elasticity of tissue
AU2002306461A1 (en) In vivo delivery methods and compositions
AU2001253812A1 (en) In vivo loading of mhc
AU2001287198A1 (en) Dental restorative compositions and method of use thereof
AU2002366809A1 (en) Syn3 compositions and methods
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
AU2002303552A1 (en) Methods and compositions for prevention of angioproliferation
AU2001274815A1 (en) Compositions and methods for inducing activation of dendritic cells
AU2001261513A1 (en) Composition and method for increasing testosterone levels